8:00 am Registration Opens

8:25 am Chair’s Opening Remarks

8:30 am The Difference a Decade Makes – The Rise of Checkpoint Inhibitors in Treating NSCLC

Emerging Approaches to Targeting NSCLC

9:00 am Progress in Newly Diagnosed Actionable Mutations

  • Ben Powell Vice President of Discovery Biology, Kinnate

Synopsis

  • Rationale for the use of novel Pan-RAF inhibitors for NSCLC
  • Critical success factors for successful Pan-RAF inhibitors
  • Next steps and the future of targeting RAF in NSCLC

9:30 am Harnessing Cancer’s Adaptive Resistance Profiles in NSCLC

Synopsis

  • Developing a novel method and algorithm for picking up resistance mechanisms
    that can not be identified via current technologies
  • Utilizing proprietary tissue culture technology termed the ResCu system to
    more accurately recapitulate the emergence of resistance seen in the clinic. The
    system captures the emergence of “crawlers” – resistant subpopulations and their
    frequency of occurrence at clinically relevant doses of small molecule inhibitors or
    biologics
  • Discussing how the cancer spheroids that are formed experience a
    microenvironment that resembles that of the human tissue. Similar pH is
    maintained under continuous fluid exchange, which mimics blood flow, allowing
    for resistance to occur under clinical PK. In totality, this enables resistanceBio to
    identify a compound’s strengths and expose critical vulnerabilities in patients’
    tumor biology

10:00 am Inhibitors of the E3 Ubiquitin Ligase CBL-B Promote Potent T & NK Cell Mediated Anti-Tumor Response

  • Ryan Rountree Senior Director, Preclinical Pharmacology, Nurix Therapeutics

Synopsis

  • CBL-B E3 ubiquitin ligase functions as a negative regulator of T cell receptor
    activation
  • Reporting the discovery of NX-1607, an orally bioavailable CBL-B inhibitor that
    demonstrates anti-tumor activity in multiple preclinical tumor models
  • NX-1607 triggers rapid NK and T cell infiltration of tumors and shows increased
    frequency of tumor rejection in combination with anti-PD-1. Our studies provide
    rationale for clinical development of NX-1607 in advanced malignancies

10:30 am Speed Networking

11:00 am Morning Refreshments

Drug Development Progress in Late-Line Non-Small Cell Lung Cancer

11:30 am Using Expanded Access Programs (EAPs) to Generate Meaningful Clinical and Real-World Evidence in Rare, Biomarker Driven NSCLC

  • Andrew Shim Executive Director, Head, Global HEOR & RWE, Medical Affairs, Oncology, Turning Point Therapeutics

Synopsis

  • Conventional clinical trials in rare, biomarker driven NSCLC patient populations are becoming increasingly challenging and competitive
  • Utilizing Expanded Access Programs to generate additional clinical and real-world evidence is becoming increasingly important
  • Balancing data collection with site personnel and patient burden for EAPs is key to achieving success

12:00 pm Taletrectinib, A Potential Best-In-Class Next-Generation ROS1 Inhibitor, Hits a Unique Balance of Excellent Efficacy & Favorable Safety Profile

  • Lihua Zheng Chief Business Officer & Co-Founder, AnHeart Therapeutics

Synopsis

  • Taletrectinib can be a practice-changing ROS1 inhibitor to meet unmet medical
    needs
  • Highly selective and potent against ROS1 and secondary resistant mutations as
    well as excellent intracranial antitumor activity
  • Well-tolerated safety profile with low incidence of CNS adverse events

12:30 pm Panel Discussion: Exploring the Strategic Challenges of Moving Forward a Drug You Want to Combine with PD-1 in Chemo+PD-1 Progressors

  • Phillip Dennis Vice President, Lung Cancer & Oncology Development, Sanofi
  • Stephen Horrigan Chief Scientific Officer, Iterion Therapeutics
  • Emmett Schmidt Vice President, Lead External Collaborations Project Team Global Clinical Development, Merck & Co
  • Michael Krainock Oncology Medical Director, Natera

Synopsis

  • Understanding the different current comparators and benchmarks
  • Exploring the differences in PD-1 naïve and PD-1 progressors
  • Dissecting why sometimes beating chemo and PD-1 could be an unachievable bar
  • Discussing whether with late-line in-effectivity, how you know it won’t work in early line?
  • Considering the health authorities’ standards on the matter

1:00 pm Lunch & Networking

Understanding PD-1 Resistance & Improved Dissection of Patient Populations in Later-Line NSCLC

2:00 pm Exploring BLU-945 in EGFR-Mutated NSCLC

  • Faris Albayya Translational Medicine Scientist, Blueprint Medicines

Synopsis

  • Exploring the latest translational research
  • Discussing potential combinations and treatment line
  • Latest data and future directions

Optimizing Sequencing & Combination Rationale in Later Lines of Therapy

2:30 pm Informed By The Tumor: The Power of a Personalized ctDNA Assay For MRD Detection & Monitoring in NSCLC

Synopsis

  • Latest clinical data from 2022 publications and presentations
  • Advantages of a personalized, tumor-informed ctDNA assay for molecular
    residual disease detection
  • Applications of Signatera in clinical trial design to maximize trial success, and
    accelerate time to data readout

3:00 pm Advancements in ADCs for later-line NSCLC

  • Phillip Dennis Vice President, Lung Cancer & Oncology Development, Sanofi

Synopsis

  • Exploring the latest translational research
  • Discussing potential combinations and treatment line
  • Latest data and future directions

3:30 pm Afternoon Refreshments

4:00 pm Synergy is a 4 Letter Word: Lessons of Independent Action as an Explanation for the Efficacy of Cancer Clinical Combination Therapies

  • Emmett Schmidt Vice President, Lead External Collaborations Project Team Global Clinical Development, Merck & Co

Synopsis

– Immuno oncology drugs are failing at an unprecedented rate, perhaps because too much reliance has been placed on pre-clinical thinking about synergy
– Based on the mathematics of Independent Action, synergy has not been seen in any immuno oncology registration trials to date
– To progress development of combinations of ADC and PD-1 immune checkpoint inhibitors, the field must adapt more rigorous mathematic thinking about combination results

4:30 pm Retrospective Analysis of a Positive Phase 3 Trial of Plinabulin/ Docetaxel Combination vs. Docetaxel in EGFR Wild-Type NSCLC (DUBLIN-3)

  • June Lu Sr. Director, Translation Medicine, BeyondSpring Pharmaceuticals Inc.

Synopsis

  • Plinabulin multifaceted MoA as an anticancer agent with severe neutropeniaprevention
    property
  • Rationale for developing Plinabulin in EGFR-wt NSCLC (and SCLC)
  • Biomarker approaches for monitoring Plinabulin intra/inter-patient activity

5:00 pm Chair’s Closing Remarks & End of Day 1